The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial (Preprint)
Authors: Kitahiro Yumi , Yamamoto Kazuhiro , Yakushijin Kimikazu , Ioroi Takeshi , Tanda Masaaki , Itohara Kotaro , Omura Tomohiro , Minami Hironobu , Yano Ikuko 
Published: November 2023

BACKGROUND

Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H<sub>1</sub>-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H<sub>1</sub>-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion.

OBJECTIVE

This study aimed to assess the efficacy of first- and second-generation histamine H<sub>1</sub>-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma.

METHODS

This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H<sub>1</sub>-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H<sub>1</sub>-receptor antagonist–induced drowsiness using the visual analogue scale, with each patient providing their individual response.

RESULTS

This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026.

CONCLUSIONS

This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H<sub>1</sub>-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion.

CLINICALTRIAL

Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169

INTERNATIONAL REGISTERED REPORT

DERR1-10.2196/54882